Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Common stock, $0.001 par value; 500,000,000 shares authorized; 204,386,699 shares issued and 195,707,702 shares outstanding as of March 31, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | 204 | 202 |
| Treasury stock, at cost; 8,678,997 shares as of March 31, 2026; 7,597,172 shares as of December 31, 2025 | (405,776) | (323,276) |
| Additional paid-in capital | 2,112,454 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (8) | 12 |
| Accumulated deficit | (3,985,237) | (3,821,194) |
| Total BridgeBio stockholders’ deficit | (2,278,363) | (2,086,610) |
| Noncontrolling interests | 10,439 | 10,599 |
| Total stockholders’ deficit | (2,267,924) | (2,076,011) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's AOCI?
- BridgeBio Pharma (BBIO) reported AOCI of -$8K in Q1 2026.
- What is the long-term trend for BridgeBio Pharma's AOCI?
- Over 5 years (2020 to 2025), BridgeBio Pharma's AOCI has grown at a -42.6% compound annual growth rate (CAGR), from $192K to $12K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about BridgeBio Pharma's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude